Monte Rosa Therapeutics
GLUENASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $10.50 Prior regular-session close from the quote source.
- $10.16–$10.55 Regular-session low and high so far today.
- 1.3M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $9.68–$25.77 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own GLUE if Monte Rosa is a platform-biotech option on whether proprietary molecular glue degraders can become a repeatable source of partnered and eventually commercial medicines before cash runway or clinical evidence runs out.
GLUE price history
Loading recent earnings…
Investment thesis
What must happen next
Pharma and biotech demand for molecular glue degrader discovery remains strong enough to fund Monte Rosa through collaboration economics rather than leaving shareholders to finance the platform alone.StrengtheningMateriality: High
GAAP annual revenue was $0 in FY2023, then $75.6 million in FY2024 and $123.7 million in FY2025, showing customer-contract monetization after a pre-revenue period. If partner demand persists, collaboration cash can extend runway and validate the platform; if it fades, the company becomes a higher-dilution clinical-stage biotech.
Watch: Large pharma partners shift discovery budgets away from molecular glue degraders toward other protein-degradation approaches or conventional small molecules.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $0 in FY2023, then $75.6 million in FY2024 and $123.7 million in FY2025, showing customer-contract monetization.
Open source ↗The balance sheet remains strong enough to let Monte Rosa reach meaningful clinical or partnership readouts without a distressed financing.HoldingMateriality: High
Cash and cash equivalents were $129.9 million at FY2025 year-end. Runway determines whether shareholders own the upside from the platform or are diluted before proof arrives.
Watch: Clinical programs require larger, longer, or repeated studies because of safety, CMC, or dose-selection issues.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $129.9 million at FY2025 year-end.
Open source ↗Management can keep the discovery platform and clinical portfolio funded without letting operating losses re-accelerate faster than the evidence base improves.StrengtheningMateriality: Medium
GAAP annual operating loss narrowed from $143.3 million in FY2023 to $81.1 million in FY2024 and $54.2 million in FY2025. A platform biotech only creates per-share value if R&D intensity buys higher probability of success, not simply larger losses.
Watch: Multiple programs move into costlier clinical stages before partner funding or proof-of-concept data support the spend.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed from $143.3 million in FY2023 to $81.1 million in FY2024 and $54.2 million in FY2025.
Open source ↗Monte Rosa retains the specialized scientific capability needed to keep generating molecular glue degrader candidates rather than depending on a single asset.StrengtheningMateriality: Medium
The company had 150 full-time employees as of December 31, 2025. The upside case is platform repeatability; if the talent engine weakens, Monte Rosa becomes a narrower binary-drug bet.
Watch: Senior chemistry, biology, translational, or clinical leaders depart for better-funded competitors or pharma partners.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company had 150 full-time employees as of December 31, 2025.
Open source ↗Monte Rosa’s non-dilutive funding model remains unproven until collaboration cash flow proves repeatable beyond upfront or one-time contract effects.HoldingMateriality: Medium
GAAP annual operating cash flow was positive $42.0 million in FY2024, then negative $22.8 million in FY2025. If operating cash flow depends on episodic payments, investors must underwrite dilution risk even when reported revenue rises.
Watch: No new milestones, option exercises, or collaboration expansions follow the prior customer-contract revenue.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive $42.0 million in FY2024, then negative $22.8 million in FY2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Pharma and biotech demand for molecular glue degrader discovery remains strong enough to fund Monte Rosa through collaboration economics rather than leaving shareholders to finance the platform alone. If partner demand persists, collaboration cash can extend runway and validate the platform; if it fades, the company becomes a higher-dilution clinical-stage biotech.
The balance sheet remains strong enough to let Monte Rosa reach meaningful clinical or partnership readouts without a distressed financing. Runway determines whether shareholders own the upside from the platform or are diluted before proof arrives.
Management can keep the discovery platform and clinical portfolio funded without letting operating losses re-accelerate faster than the evidence base improves. A platform biotech only creates per-share value if R&D intensity buys higher probability of success, not simply larger losses.
Monte Rosa retains the specialized scientific capability needed to keep generating molecular glue degrader candidates rather than depending on a single asset. The upside case is platform repeatability; if the talent engine weakens, Monte Rosa becomes a narrower binary-drug bet.
Monte Rosa’s non-dilutive funding model remains unproven until collaboration cash flow proves repeatable beyond upfront or one-time contract effects. If operating cash flow depends on episodic payments, investors must underwrite dilution risk even when reported revenue rises.
All standing thesis claims
Original report summary
Monte Rosa is a platform-biotech option on whether proprietary molecular glue degraders can become a repeatable source of partnered and eventually commercial medicines before cash runway or clinical evidence runs out.
Bull case and bear case
Bull case and bear case for Monte Rosa Therapeutics
Where the evidence on Monte Rosa Therapeutics stands: Holding on the latest evidence (Nov 9, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Pharma and biotech demand for molecular glue degrader discovery remains strong enough to fund Monte Rosa through collaboration economics rather than leaving shareholders to finance the platform alone.
The balance sheet remains strong enough to let Monte Rosa reach meaningful clinical or partnership readouts without a distressed financing.
Management can keep the discovery platform and clinical portfolio funded without letting operating losses re-accelerate faster than the evidence base improves.
Monte Rosa retains the specialized scientific capability needed to keep generating molecular glue degrader candidates rather than depending on a single asset.
Monte Rosa’s non-dilutive funding model remains unproven until collaboration cash flow proves repeatable beyond upfront or one-time contract effects.
Bear case: what would count against it
Large pharma partners shift discovery budgets away from molecular glue degraders toward other protein-degradation approaches or conventional small molecules.
Clinical programs require larger, longer, or repeated studies because of safety, CMC, or dose-selection issues.
Multiple programs move into costlier clinical stages before partner funding or proof-of-concept data support the spend.
Thesis-Break Engine
Thesis-break watch · Monte Rosa Therapeutics
Loading the break-condition record for Monte Rosa Therapeutics.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Monte Rosa Therapeutics filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Monte Rosa Therapeutics filed an SEC 8-K on 2026-10-01: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Monte Rosa Therapeutics filed an SEC 8-K on 2026-09-08: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large pharma partners shift discovery budgets away from molecular glue degraders toward other protein-degradation approaches or conventional small molecules.
- Clinical programs require larger, longer, or repeated studies because of safety, CMC, or dose-selection issues.
- Multiple programs move into costlier clinical stages before partner funding or proof-of-concept data support the spend.
- Senior chemistry, biology, translational, or clinical leaders depart for better-funded competitors or pharma partners.
- No new milestones, option exercises, or collaboration expansions follow the prior customer-contract revenue.
GLUE news
Loading headlines…
Financial statements
GLUE income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
GLUE: quick answers
- Which well-known investors own GLUE?
- 1 of the 37 well-known funds tracked here reported GLUE shares in their latest 13F filing. By share of the fund's portfolio: Duquesne Family Office (Stanley Druckenmiller), 0.1%. Fund portfolios
GLUE in well-known investors’ portfolios
1 of 37 funds reported GLUE shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Stanley DruckenmillerDuquesne Family Office | 0.14% | $7.2M | New | Q2 2026 |